Amidst the battle of the world against CoViD-19, there was a drug which shows promising results to combat this deadly Virus. This is a Chinese-based Capsule named Lianhua Quingwin Jiaonang. In relation to CoViD-19, this product was first registered on 1st of February on The Chinese Clinical Trial Registry. During this Trial, there was a total of 284 CoViD-19 patients from 23 Hospitals were involved. According to its study design, the intervention given include routine treatment and four Capsules of Lianhua Quingwin each time or one bag of Lianhua Quingwin granules three times a day. According to that said study, there was about 83.8% of the patients in the treatment group saw an improvement in their lung scan images, and 78.9% recovered. So, what is the fuss about? What is this drug then, and how was it developed? The Lianhua Quingwin medication was first developed in China in the year 2003, specifically in response to the SARS outbreak in China. In July 2003, the first Lianhua Quingwi